100
Participants
Start Date
October 20, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
GTX-104
Nimodipine IV infusion
Nimotop 30 MG Oral Capsule
Oral nimodipine capsules
The Mount Sinai Hospital, New York
University of Maryland Medical Center, Baltimore
Virginia Commonwealth University, Richmond
University of North Carolina, Chapel Hill
Duke University, Durham
Emory University School of Medicine Emergency Neurosciences, Atlanta
Mayo Clinic Florida, Jacksonville
The University of Alabama at Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
Methodist University Hospital, Memphis
University of Kentucky Hospital, Lexington
The Ohio State University Wexner Medical Center, Columbus
University Hospitals Cleveland Medical Center, Cleveland
University of Cincinnati Medical Center, Cincinnati
Indiana University Health Methodist Hospital, Indianapolis
Northwestern Feinberg Pavillion Neuro and Spine ICU, Chicago
Washington University, St Louis
University of Texas Health Science Center at Houston, Houston
Brain and Spine Neurological Institute, Phoenix
Community Regional Medical Center, Fresno
Oregon Health and Science University, Portland
Beth Israel Deaconess Medical Center, Boston
Lead Sponsor
Grace Therapeutics Inc.
INDUSTRY